Trump Announces Drug Pricing Deal with Regeneron

President Donald Trump will announce a drug pricing agreement with Regeneron Pharmaceuticals on Thursday afternoon at the White House, marking the final deal in a series of pacts aimed at reducing costs for American patients.

The agreement requires Regeneron to lower prices for its current and future medications under the Medicaid program, which serves low-income individuals. It also includes offering the company's cholesterol-lowering drug Praluent for $225 through the TrumpRx website, a government portal connecting consumers to discounted pharmaceuticals. According to White House officials, Regeneron has committed nearly $10 billion to expand pharmaceutical manufacturing in the United States, a provision tied to relief from certain tariffs.

This deal concludes a year-long initiative launched by Trump last July, when he sent letters to executives at 17 major drugmakers urging them to align U.S. prices with the lower rates paid in other developed countries. Regeneron, known for products like Dupixent for eczema and Eylea for eye conditions, was the last to reach an accord. Other companies, including Pfizer, Eli Lilly and Amgen, have already signed similar agreements to cut...